Center for MINDS: Bruce Damer on Why We Need Psychedelic-Catalysed Innovation Post published:February 5, 2026 Post category:Analysis/Interviews/News
The Psychedelic News Feed: January 26 – Febraury 1, 2026 Post published:February 2, 2026 Post category:Psychedelic News Feed Archive
Q3 2025: Oregon Psilocybin Services Update Post published:February 2, 2026 Post category:Analysis/News/Pα+
āChanges Are Never Linearā: Joost Breeksema on the Human Side of Psychedelic Therapy Post published:January 27, 2026 Post category:Interviews
The Psychedelic News Feed: January 19 – 25, 2025 Post published:January 27, 2026 Post category:Psychedelic News Feed Archive
Op-Ed: From Psychedelic Prohibition to Psychedelic Public Health Post published:January 26, 2026 Post category:2025 Year in Review/Opinions
Pα+ Psychedelic Bulletin #218: FDAās Farchione Says Psychedelic INDs Are āa Thirdā of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in PPD; America’s 10 Million Microdosers Post published:January 22, 2026 Post category:Psychedelic Bulletin/Pα+
Psychedelic Funding, Public Markets, and M&A in 2025 Post published:January 20, 2026 Post category:2025 Year in Review/Analysis/Pα+
Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europeās Real World Post published:January 19, 2026 Post category:2025 Year in Review/Opinions